{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:44:25Z","timestamp":1787010265997,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Sexual Trans Dis"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2023, Washington state Medicaid eliminated prior authorizations (PAs) for antiretrovirals (ARVs). We estimated the budget impact of this policy change on Medicaid ARV expenditures, 2023 to 2027.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Models used 2022 net drug costs reflecting costs minus rebates. Our base case preexposure prophylaxis (PrEP) model assumed changes in the proportions of PrEP users on tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC), tenofovir alafenamide\/emtricitabine (TAF\/FTC), and cabotegravir (CAB) based on 2021\u20132022 data (before elimination of PAs). We compared base case costs to models assuming changes in PrEP prescribing observed in 2022 to 2023 (first year after elimination of PAs) and models assuming an accelerated increase in TAF\/FTC and CAB use. For HIV treatment, models assuming ARV changes based on 2021 to 2022 data (Base Model), changes based on data from 2022 to 2023 (No PA\u2014Stable Increase), and a model based on 2022 to 2023 data but with a declining rate of change in the adoption of bictegravir\/TAF\/FTC and CAB\/rilpivirine (No PA\u2014Declining Increase). We estimated the number of persons with HIV who might be housed using money required to meet new ARV costs using 2023 local Ryan White Program costs for emergency or temporary housing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elimination of PAs will increase Medicaid expenditures for ARVs by an estimated $109.9 to $157.7 million over 5 years. This cost would pay for 5 years of housing for approximately 820 to 1177 people, or 61% to 88% of unstably housed persons with HIV in Washington state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elimination of Medicaid PAs will result in substantial new costs. Changes in drug formulary policy should consider opportunity costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/olq.0000000000002136","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:00:48Z","timestamp":1739260848000},"page":"370-375","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Budget Impact of Eliminating Medicaid Prior Authorizations for Antiretrovirals in Washington State"],"prefix":"10.1097","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-3774","authenticated-orcid":false,"given":"Matthew R.","family":"Golden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Taketomo","sequence":"additional","affiliation":[{"name":"Washington State Health Care Authority, Olympia, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Pistoresi","sequence":"additional","affiliation":[{"name":"Washington State Health Care Authority, Olympia, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Washington State Health Care Authority, Olympia, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"bib1-20250509","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: Recent estimates and future implications","volume":"26","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"bib2-20250509","doi-asserted-by":"crossref","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: A systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","year":"2022","journal-title":"BMJ Open"},{"key":"bib3-20250509","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"bib4-20250509","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib5-20250509","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/OLQ.0000000000001366","article-title":"Estimated lifetime HIV-related medical costs in the United States","volume":"48","year":"2021","journal-title":"Sex Transm Dis"},{"key":"bib6-20250509","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/cid\/civ1000","article-title":"The Epi-TAF for tenofovir disoproxil fumarate?","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"bib7-20250509","first-page":"S173","article-title":"Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: An economic evaluation of a clinical trial","volume":"35","year":"2021","journal-title":"AIDS"},{"key":"bib8-20250509","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7326\/L20-0693","article-title":"Comparative pricing of branded tenofovir alafenamide-emtricitabine relative to generic tenofovir disoproxil fumarate-emtricitabine for HIV preexposure prophylaxis","volume":"173","year":"2020","journal-title":"Ann Intern Med"},{"key":"bib9-20250509","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/M21-1548","article-title":"Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: A cost-effectiveness analysis","volume":"175","year":"2022","journal-title":"Ann Intern Med"},{"key":"bib10-20250509","first-page":"386","article-title":"Global HIV incidence analysis and implications for affordability using long-acting cabotegravir versus continuous and event-driven oral preexposure prophylaxis","volume":"78","year":"2023","journal-title":"Clin Infect Dis"},{"key":"bib17-20250509","article-title":"Gilead Sciences Fourth Quarter and Full Year 2023 Earnings Prepared Remarks","year":"2024","journal-title":"Gilead Sciences"},{"key":"bib19-20250509","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","article-title":"How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP","volume":"4","year":"2018","journal-title":"J Virus Erad"},{"key":"bib20-20250509","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): Primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"bib21-20250509","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2023.9865","article-title":"Preexposure prophylaxis for the prevention of HIV: Updated evidence report and systematic review for the US Preventive Services Task Force","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"bib25-20250509","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate: An updated meta-analysis of 14 894 patients across 14 trials","volume":"34","year":"2020","journal-title":"AIDS"},{"key":"bib27-20250509","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.therap.2020.12.017","article-title":"Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen","volume":"76","year":"2021","journal-title":"Therapie"},{"key":"bib28-20250509","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","year":"2018","journal-title":"AIDS Res Ther"}],"container-title":["Sexually Transmitted Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/OLQ.0000000000002136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:00:51Z","timestamp":1746777651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/OLQ.0000000000002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/olq.0000000000002136","relation":{},"ISSN":["1537-4521","0148-5717"],"issn-type":[{"value":"1537-4521","type":"electronic"},{"value":"0148-5717","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}